Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.
Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, Pumphrey NJ, Bennett AD, Brewer JE, Dukes J, Harper J, Tayton-Martin HK, Jakobsen BK, Hassan NJ, Kalos M, June CH. Linette GP, et al. Among authors: pumphrey nj. Blood. 2013 Aug 8;122(6):863-71. doi: 10.1182/blood-2013-03-490565. Epub 2013 Jun 14. Blood. 2013. PMID: 23770775 Free PMC article.
Human TCR-binding affinity is governed by MHC class restriction.
Cole DK, Pumphrey NJ, Boulter JM, Sami M, Bell JI, Gostick E, Price DA, Gao GF, Sewell AK, Jakobsen BK. Cole DK, et al. Among authors: pumphrey nj. J Immunol. 2007 May 1;178(9):5727-34. doi: 10.4049/jimmunol.178.9.5727. J Immunol. 2007. PMID: 17442956
High affinity soluble ILT2 receptor: a potent inhibitor of CD8(+) T cell activation.
Moysey RK, Li Y, Paston SJ, Baston EE, Sami MS, Cameron BJ, Gavarret J, Todorov P, Vuidepot A, Dunn SM, Pumphrey NJ, Adams KJ, Yuan F, Dennis RE, Sutton DH, Johnson AD, Brewer JE, Ashfield R, Lissin NM, Jakobsen BK. Moysey RK, et al. Among authors: pumphrey nj. Protein Cell. 2010 Dec;1(12):1118-27. doi: 10.1007/s13238-010-0144-5. Epub 2011 Jan 8. Protein Cell. 2010. PMID: 21213105 Free PMC article.
Monoclonal TCR-redirected tumor cell killing.
Liddy N, Bossi G, Adams KJ, Lissina A, Mahon TM, Hassan NJ, Gavarret J, Bianchi FC, Pumphrey NJ, Ladell K, Gostick E, Sewell AK, Lissin NM, Harwood NE, Molloy PE, Li Y, Cameron BJ, Sami M, Baston EE, Todorov PT, Paston SJ, Dennis RE, Harper JV, Dunn SM, Ashfield R, Johnson A, McGrath Y, Plesa G, June CH, Kalos M, Price DA, Vuidepot A, Williams DD, Sutton DH, Jakobsen BK. Liddy N, et al. Among authors: pumphrey nj. Nat Med. 2012 Jun;18(6):980-7. doi: 10.1038/nm.2764. Nat Med. 2012. PMID: 22561687
Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, Bossi G, Vuidepot A, Powlesland AS, Legg A, Adams KJ, Bennett AD, Pumphrey NJ, Williams DD, Binder-Scholl G, Kulikovskaya I, Levine BL, Riley JL, Varela-Rohena A, Stadtmauer EA, Rapoport AP, Linette GP, June CH, Hassan NJ, Kalos M, Jakobsen BK. Cameron BJ, et al. Among authors: pumphrey nj. Sci Transl Med. 2013 Aug 7;5(197):197ra103. doi: 10.1126/scitranslmed.3006034. Sci Transl Med. 2013. PMID: 23926201 Free PMC article.
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.
Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, Kulikovskaya I, Sinha SK, Kronsberg S, Gupta M, Bond S, Melchiori L, Brewer JE, Bennett AD, Gerry AB, Pumphrey NJ, Williams D, Tayton-Martin HK, Ribeiro L, Holdich T, Yanovich S, Hardy N, Yared J, Kerr N, Philip S, Westphal S, Siegel DL, Levine BL, Jakobsen BK, Kalos M, June CH. Rapoport AP, et al. Among authors: pumphrey nj. Nat Med. 2015 Aug;21(8):914-921. doi: 10.1038/nm.3910. Epub 2015 Jul 20. Nat Med. 2015. PMID: 26193344 Free PMC article.
Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer.
Docta RY, Ferronha T, Sanderson JP, Weissensteiner T, Pope GR, Bennett AD, Pumphrey NJ, Ferjentsik Z, Quinn LL, Wiedermann GE, Anderson VE, Saini M, Maroto M, Norry E, Gerry AB. Docta RY, et al. Among authors: pumphrey nj. Hepatology. 2019 May;69(5):2061-2075. doi: 10.1002/hep.30477. Epub 2019 Feb 14. Hepatology. 2019. PMID: 30561769 Free PMC article.
18 results